Skip to the main content

Original scientific paper

Argon plasma coagulation as therapy in treatment of Barret's esophagus

Melanija Ražov Radas orcid id orcid.org/0000-0003-4530-4350 ; Opća bolnica Zadar, Služba za internu medicinu, Odjel za gastroenterologiju


Full text: croatian pdf 469 Kb

page 5-12

downloads: 596

cite


Abstract

The aim of this study was to evaluate the effect of argon plasma coagulation (APC) in the treatment of Barrett’s esophagus (BE) and confirm the expression of Mucin 2 glycoprotein (MUC2) and Vascular Endothelial Growth Factor (VEGF) in Barrett’s mucosa before and/or after APC treatment. A higher expression of MUC2 and VEGF in Barrett's mucosa may be associated with a higher risk for the development of adenocarcinoma (AC). The study included five patients with diagnosis of BE, short-segment. The inclusion criteria was unsuccessful treatment with proton pump inhibitors (PPI). The diagnosis was confirmed by patohystological (PH) analysis after EGJ biopsy. The expression of MUC2 and VEGF was performed with immunohistochemistry. After various APC treatments, the complete recovery of EGJ mucosa occurred in IM patients. The recovery was not achieved in patients with dysplastic change of tissue. There were no malignant developments. These patients remained on PPI therapy and regular endoscopic control. We found histological regression of BE in Gastroesophageal reflux disease (GERD) in four patients. The patients informed us about their clinical improvement: they had less, or completely no symptoms of regurgitation, burning phenomenon and dyspepsia that were leading symptoms due to which they were brought to our hospital.

Keywords

Barrett's esophagus; argon plasma coagulation; proton pump inhibitors

Hrčak ID:

197845

URI

https://hrcak.srce.hr/197845

Publication date:

27.3.2018.

Article data in other languages: croatian

Visits: 2.186 *